27 research outputs found
Pulmonary drug delivery: Role of antibiotic formulations for treatment of respiratory tract infections
Respiratory infections cause an extensive health problem in the world. The common treatment for respiratory infections is the administration of antibiotics orally or parenterally in a high dose. Unfortunately, these therapies of high-dose antimicrobials have many disadvantages, such as severe side effects. Consequently, the development of an inhaled formulation provides the delivery of the therapeutic dose of the drug to the organ of interest without overt systemic effects. Novel technological advances have led to the development of inhaled antibiotics. Recent particle engineering techniques for dry powder inhalers (DPI) or mesh nebulizers have higher aerosolization efficiencies and promote the delivery of high-dose antibiotics to the lungs. However, advanced formulation strategies are in high demand for the development of new formulations for more types of antibiotics. Despite all the current research, patient compliance with pulmonary dosage forms remains to be very low because of the inappropriate administration techniques. Hence, this review focuses on three key aspects of the pulmonary dosage forms of antibiotics; the marketed products, the formulation approaches under research and innovative formulation strategies for achieving drug delivery through the respiratory tract
Nanopharmaceuticals: A Boon to the Brain-Targeted Drug Delivery
Brain is well known for its multifarious nature and complicated diseases. Brain consists of natural barriers that pose difficulty for the therapeutic agents to reach the brain tissues. Blood-brain barrier is the major barrier while blood-brain tumor barrier, blood-cerebrospinal (CSF) barrier and efflux pump impart additional hindrance. Therapeutic goal is to achieve a considerable drug concentration in the brain tissues in order to obtain desired therapeutic outcomes. To overcome the barriers, nanotechnology was employed in the field of drug delivery and brain targeting. Nanopharmaceuticals are rapidly emerging sub-branch that deals with the drug-loaded nanocarriers or nanomaterials that have unique physicochemical properties and minute size range for penetrating the CNS. Additionally, nanopharmaceuticals can be tailored with functional modalities to achieve active targeting to the brain tissues. The magic behind their therapeutic success is the reduced amount of dose and lesser toxicity, whereby localizing the therapeutic agent to the specific site. Different types of nanopharmaceuticals like polymeric, lipidic and amphiphilic nanocarriers were administered into the living organisms by exploiting different routes for improved targeted therapy. Therefore, it is essential to throw light on the properties, mechanism and delivery route of the major nanopharmaceuticals that are employed for the brain-specific drug delivery
Application of Nanotechnology for Sensitive Detection of Low-Abundance Single-Nucleotide Variations in Genomic DNA: A Review
Single-nucleotide polymorphisms (SNPs) are the simplest and most common type of
DNA variations in the human genome. This class of attractive genetic markers, along with point
mutations, have been associated with the risk of developing a wide range of diseases, including
cancer, cardiovascular diseases, autoimmune diseases, and neurodegenerative diseases. Several
existing methods to detect SNPs and mutations in body fluids have faced limitations. Therefore,
there is a need to focus on developing noninvasive future polymerase chain reaction (PCR)–free tools
to detect low-abundant SNPs in such specimens. The detection of small concentrations of SNPs in
the presence of a large background of wild-type genes is the biggest hurdle. Hence, the screening
and detection of SNPs need efficient and straightforward strategies. Suitable amplification methods
are being explored to avoid high-throughput settings and laborious efforts. Therefore, currently,
DNA sensing methods are being explored for the ultrasensitive detection of SNPs based on the
concept of nanotechnology. Owing to their small size and improved surface area, nanomaterials hold
the extensive capacity to be used as biosensors in the genotyping and highly sensitive recognition
of single-base mismatch in the presence of incomparable wild-type DNA fragments. Different
nanomaterials have been combined with imaging and sensing techniques and amplification methods
to facilitate the less time-consuming and easy detection of SNPs in different diseases. This review
aims to highlight some of the most recent findings on the aspects of nanotechnology-based SNP
sensing methods used for the specific and ultrasensitive detection of low-concentration SNPs and
rare mutations
Active Targeted of Nanoparticles for Delivery of Poly(ADP ribose) Polymerase (PARP) Inhibitors: A Preliminary Review
Nanotechnology has revolutionized novel drug delivery strategies through establishing nanoscale drug carriers, such as niosomes, liposomes, nanomicelles, dendrimers, polymeric micelles, and nanoparticles (NPs). Owing to their desirable cancer-targeting efficacy and controlled release, these nanotherapeutic modalities are broadly used in clinics to improve the efficacy of small-molecule inhibitors. Poly(ADP-ribose) polymerase (PARP) family members engage in various intracellular processes, including DNA repair, gene transcription, signal transduction, cell cycle regulation, cell division, and antioxidant response. PARP inhibitors are synthetic small-molecules that have emerged as one of the most successful innovative strategies for targeted therapy in cancer cells harboring mutations in DNA repair genes. Despite these advances, drug resistance and unwanted side effects are two significant drawbacks to using PARP inhibitors in the clinic. Recently, the development of practical nanotechnology-based drug delivery systems has tremendously improved the efficacy of PARP inhibitors. NPs can specifically accumulate in the leaky vasculature of the tumor and cancer cells and release the chemotherapeutic moiety in the tumor microenvironment. On the contrary, NPs are usually unable to permeate across the body's normal organs and tissues; hence the toxicity is zero to none. NPs can modify the release of encapsulated drugs based on the composition of the coating substance. Delivering PARP inhibitors without modulation often leads to the toxic effect; therefore, a delivery vehicle is essential to encapsulate them. Various nanocarriers have been exploited to deliver PARP inhibitors in different cancers. Through this review, we hope to cast light on the most innovative advances in applying PARP inhibitors for therapeutic purposes.(Comunidad de Madrid
Nanodiagnosis and Nanotreatment of Cardiovascular Diseases: An Overview
Cardiovascular diseases (CVDs) are the world’s leading cause of mortality and represent a
large contributor to the costs of medical care. Although tremendous progress has been made for the
diagnosis of CVDs, there is an important need for more effective early diagnosis and the design of
novel diagnostic methods. The diagnosis of CVDs generally relies on signs and symptoms depending
on molecular imaging (MI) or on CVD-associated biomarkers. For early-stage CVDs, however,
the reliability, specificity, and accuracy of the analysis is still problematic. Because of their unique
chemical and physical properties, nanomaterial systems have been recognized as potential candidates
to enhance the functional use of diagnostic instruments. Nanomaterials such as gold nanoparticles,
carbon nanotubes, quantum dots, lipids, and polymeric nanoparticles represent novel sources to
target CVDs. The special properties of nanomaterials including surface energy and topographies
actively enhance the cellular response within CVDs. The availability of newly advanced techniques
in nanomaterial science opens new avenues for the targeting of CVDs. The successful application of
nanomaterials for CVDs needs a detailed understanding of both the disease and targeting moieties